CPDR is a program of the Uniformed Services University of the Health Sciences
and the Henry M. Jackson Foundation for the Advancement of Military Medicine

banner


> Publications

> 2002 Publications

 

1. p63 Expression Profile in Normal and Malignant Prostate Epithelial Cells.
Davis LD, Zhang W, Merseburger AS, Young D, Xu LL, Rhim JS, Moul JW, Srivastava S and Sesterhenn IA.
Anticancer Research, 22:3819-3826, 2002.
2. HEPSIN Inhibits Cell Growth/Invasion in Prostate Cancer Cells.
Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S:
Cancer Res. 62(23): 6812-6, 2002.
3. Androgen-Induced Expression of Endoplasmic Reticulum (ER) Stress Response Genes in Prostate Cancer Cells.
Segawa T, Nau M, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul, Judd W, Vahey M, and Srivastava S.
Oncogene, 21, 2002.
4. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients.
Desai A, Wu H, Sun L, Sesterhenn IA, Mostofi FK, McLeod D, Amling C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW:
Prostate Cancer and Prostatic Diseases. 5: 212-218, 2002.
5. Investigating the distribution of prostate cancer using three-dimensional computer simulation.
Opell MB, Zeng J, Bauer JJ, Connelly RR, Zhang W, Sesterhenn IA, Mun SK, Moul JW and Lynch JH:
Prostate Cancer and Prostatic Diseases. 5:204-209, 2002.
6. Molecular Markers in Prostate Cancer: The Role in Preoperative Staging.
Moul JW, Merseburger A, Srivastava S:
Clinical Prostate Cancer 1:42-50, 2002.
7. Improved Prostate Cancer-Specific Survival and Other Disease Parameters: Impact of Prostate-Specific Testing.
Paquette E, Sun L. Paquette LR, Connelly R, McLeod DG, and Moul JW:
Urology 60:756-759, 2002.
8. Maspin Expression Profile in Human Prostate Cancer (CaP) and in vitro induction of Maspin expression by Androgen Ablation.
Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S and Sesterhenn I.
Clinical Cancer Research 8:1172-1177, 2002.
9. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE and McLeod DG:
Prostate Cancer and Prostatic Diseases. 5:304-310, 2002.
10. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
Koff SG, Connelly RR, Bauer JJ, McLeod DG, and Moul JW:
Prostate Cancer and Prostatic Diseases. 5:152-158, 2002.
11. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > 40 ng/mL.
Vanasupa BP, Paquette EL, Wu H, Sun L, McLeod DG, and Moul JW:
Urol. Onc. 7:167-172, 2002.

12. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI:
Oncology (Huntingt), 16:1024-38,1042; discussion 1042, 1047-8, 1051, 2002.
13. Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis.
Henderson CG, Griewe GL, Siegel TS, Peppas DS, Esther TA, Moul JW:
J Urol. 168:638-9, 2002.
14. Curcumin Down-Regulates AR Gene Expression and Activation in Prostate Cancer Cell Lines.
Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S and Rhim JS:
Int J of Oncol., 21:825-830, 2002.
15. A novel gene DERPC located on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors.
Sun M, Ma L, Xu L, Li J, Zhang W, Petrovics G, Makarem M, Sesterhenn I, Zhang M, Blanchette-Mackie EJ, Moul JW, Srivastava S and Zou Z:
Molecular Medicine 8: 654-662, 2002.
16. Cadmium-induced neoplastic transformation of human prostate epithelial cells.
Nakamura K, Yasunaga Y, Ko D, Xu LL, Moul JW, Peehl DM, Srivastava S, Rhim JS.
Int J Oncol. 20:543-7, 2002.
17. Prostate biopsy quantitative histology as a staging and prognostic factor.
Moul JW.
J Urol. 167:526-7, 2002.
18. Outcome research: prostate cancer databases.
Moul JW:
Urol Oncol, 7:39-42, 2002.
19. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI:
Oncology (Huntingt), 16:1218-24, 2002.
20. Contralateral testicular biopsy procedure in-patients with unilateral testis cancer: is it indicated?
Heidenreich A, Moul JW:
Semin Urol Oncol, 20:234-8, 2002.
Back to Top | Next Page
Disclaimer | © 2005 CPDR. All Rights Reserved.